Business Wire

Owlet Makes Premium Monitoring Possible for Every Family With New Dream Sight™ Video Monitor

9.9.2025 13:45:00 CEST | Business Wire | Press Release

Share

Owlet, Inc. (NYSE: OWLT) (the “Company” or “Owlet”), the pioneer of smart infant monitoring, announces the launch of its new HD video baby monitor, Dream Sight™, and next-generation Dream Duo™. These products represent an important step for Owlet in the category, featuring advanced technology designed to provide clarity, connection, and peace of mind from day one.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909618049/en/

Owlet's Dream Sight 2K HD Video Monitor.

“Parents are clear about what they need in a baby monitor – more advanced features, greater reliability, deeper security, and a price point that makes sense,” said Kurt Workman, Owlet’s Chief Executive Officer and Co-Founder. “Dream Sight is a direct response to that feedback from our customers. When paired with our medically-certified Dream Sock®, it creates a connected monitoring experience that gives caregivers the confidence and peace of mind they need.”

Introducing Dream Sight: Big Tech, Right Price

The Company’s smartest and most affordable camera yet, Dream Sight, provides smart HD video monitoring for confidence in every moment. Offering premium features at a lower price, Dream Sight is equipped with 2K HD resolution, motion, sound, and cry detection to alert parents when Baby needs attention, two-way talk capabilities to allow parents to soothe Baby from anywhere, automatic video clip capture and save, and temperature and humidity monitoring to help maintain a safe, comfortable sleep space. Dream Sight is also protected by industry-leading 256-bit encryption and privacy safeguards to keep video feeds secure and to ensure moments stay private. Dream Sight can be used standalone, and also pairs seamlessly with FDA-cleared, medically-certified Dream Socksmart baby monitor and the Owlet Dream App (iOS and Android) for a complete health monitoring and video solution.

New Dream Duo: The Ultimate All-in-One Monitor

Dream Sight and the Company’s award-winning Dream Sock come together in a single integrated system. Dream Duo pairs Dream Sock, which tracks Baby’s oxygen level, pulse rate, and sleep trends with hospital-grade accuracy, with Dream Sight for complete visibility day or night. This product bundle brings families enhanced reassurance with real-time alerts if vital health readings fall outside preset zones.

More Than a Monitor: Support When Parents Need It Most

With the introduction of Dream Sight and next-generation Dream Duo, Owlet is not only expanding access to smarter, more secure monitoring solutions but also reshaping the role these products play in the parenting experience. The postpartum period can be one of the most vulnerable chapters in a parent's life, defined by sleepless nights, anxiety, and the constant fear of the unknown. In this critical time, Owlet becomes more than a monitor. It's a lifeline. Parents who use Owlet report transformative outcomes: 96% experience reduced anxiety and 94% say they sleep better. These numbers underscore a deeper truth: Owlet isn’t just monitoring babies, it’s helping parents feel safe, supported, and seen.

“These latest innovations from Owlet mark a significant development in the evolution of baby monitoring, where advanced technology meets emotional well-being for parents around the world,” said Jonathan Harris, Owlet’s President. “Dream Sight addresses an important need in the global market by making premium HD monitoring accessible at an unprecedented price, while Dream Duo remains the only all-in-one system that delivers clinically validated health tracking alongside video and sleep insights.”

Dream Sight retails for $99.99 (USD) and is now available in the U.S., Canada, the UK, and across Europe. Dream Duo retails for $379.99 (USD) and is available in select markets, including the U.S., the UK, and across Europe. Available as an optional upgrade, a subscription to Owlet360™ (U.S. only, international access expected in the future) enhances the experience with advanced features to help caregivers navigate every stage with confidence, including sleep position monitoring, comfort temperature tracking, and daily historical insights about Baby’s vitals. All Owlet products are available via the Company’s e-commerce sites and retailers, including Amazon, Target, Walmart, John Lewis, BabyOne, and more. For more details, please visit www.owletcare.com.

About Owlet, Inc.

Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE: OWLT), a small-cap healthcare growth equity, offers FDA-cleared medical and consumer pediatric wearables and an integrated HD visual and audio camera that provides real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.

Since 2012, over two million parents worldwide have used Owlet’s platform, contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life. To learn more, visit www.owletcare.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the launch, commercialization, adoption, availability and market reception of Dream Sight™ and next-generation Dream Duo™, as well as the Company’s growth prospects, expanded product and service offerings, and availability in the U.S. and international markets. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the availability of, adoption and commercial success of Dream Sight and Dream Duo in the U.S. and international markets, (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iii) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (iv) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (v) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (vi) Owlet’s ability to maintain relationships with customers, manufacturers and suppliers; (vii) impacts from compliance with applicable laws or regulations; (viii) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (ix) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (x) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909618049/en/

Contacts

Owlet Media Contact:
pr@owletcare.com

Owlet Investor Contact:
ir@owletcare.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release

Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye